Publicacións en colaboración con investigadores/as de Hospital Universitari Germans Trias i Pujol (20)

2024

  1. The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy

    Clinical and Translational Oncology, Vol. 26, Núm. 7, pp. 1779-1789

2023

  1. Brief report: High incidence of peridiagnosis thromboembolic events in patients with BRAF-mutant lung cancer

    Thrombosis Research, Vol. 232, pp. 133-137

2021

  1. LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology

    Cancer Medicine, Vol. 10, Núm. 17, pp. 5878-5888

  2. Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group

    BMC Cancer, Vol. 21, Núm. 1

2020

  1. Assessment of the psychosocial and economic impact according to sex in non-small cell lung cancer patients: an exploratory longitudinal study

    BMC Psychology, Vol. 8, Núm. 1

2019

  1. Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non–Small Cell Lung Carcinoma: the ROSING Study

    Journal of Thoracic Oncology, Vol. 14, Núm. 12, pp. 2120-2132

  2. Lung cancer in Spanish women: The WORLD07 project

    European Journal of Cancer Care, Vol. 28, Núm. 1

2018

  1. Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis

    The Lancet Respiratory Medicine, Vol. 6, Núm. 10, pp. 771-781

2017

  1. Correlation of DNA Repair Gene Polymorphisms With Clinical Outcome in Patients With Locally Advanced Non–Small-Cell Lung Cancer Receiving Induction Chemotherapy Followed by Surgery

    Clinical Lung Cancer, Vol. 18, Núm. 2, pp. 178-188.e4

  2. Efficacy of tyrosine kinase inhibitors in EGFR-mutant lung cancer women in a real-world setting: the WORLD07 database

    Clinical and Translational Oncology, Vol. 19, Núm. 12, pp. 1537-1542

  3. Long-term survival in advanced non-squamous NSCLC patients treated with first-line bevacizumab-based therapy

    Clinical and Translational Oncology, Vol. 19, Núm. 2, pp. 219-226

  4. Lung Cancer in Never-Smoking Women: A Sub-Analysis of the Spanish Female-Specific Database WORLD07

    Cancer Investigation, Vol. 35, Núm. 5, pp. 358-365

2013

  1. Randomized phase II trial of non-platinum induction or consolidation chemotherapy plus concomitant chemoradiation in stage III NSCLC patients: Mature results of the Spanish Lung Cancer Group 0008 study

    Lung Cancer, Vol. 81, Núm. 1, pp. 84-90

2012

  1. Lung adenocarcinoma

    Molecular-Based Decision Making for Personalized Cancer Management (Future Medicine Ltd.), pp. 136-165

2009

  1. Predictors of long-term survival in patients with lung cancer included in the Randomized Spanish Lung Cancer Group 0008 Phase II trial using concomitant chemoradiation with docetaxel and carboplatin plus induction or consolidation chemotherapy

    Clinical Lung Cancer, Vol. 10, Núm. 3, pp. 180-186

2008

  1. Can we customize chemotherapy? individualizing cytotoxic regimens in advanced non-small-cell lung cancer

    Clinical Lung Cancer, Vol. 9, Núm. SUPPL. 2

  2. Long-term survival associated with complete resection following neoadjuvant chemotherapy in stage IIIA (N2) and IIIB (T4 N0-1) non-small cell lung cancer: A case study of the SLCG 99/01 study

    American Journal of Hematology/ Oncology, Vol. 7, Núm. 3

2003

  1. Gemcitabine and carboplatin in advanced transitional cell carcinoma of the urinary tract: An alternative therapy

    Cancer, Vol. 97, Núm. 9, pp. 2180-2186

  2. Sequential dose-dense paclitaxel followed by topotecan in untreated extensive-stage small-cell lung cancer: A Spanish Lung Cancer Group phase II study

    Annals of Oncology, Vol. 14, Núm. 10, pp. 1549-1554

  3. Three-week schedule of irinotecan and cisplatin in advanced non-small cell lung cancer: A multicentre phase II study

    Lung Cancer, Vol. 39, Núm. 2, pp. 201-207